Maine Judiciary Committee weighs six abortion-related bills; panel splits on coverage and reporting

The Joint Standing Committee on the Judiciary met to consider six bills that would alter multiple aspects of abortion law in Maine, including MaineCare coverage, reporting and data collection, post-viability rules, criminal penalties for unlicensed practice, regulation of medication abortions and informed-consent requirements.

Janet Sogo, the Legislature's Office of Policy, Legal Analysis (OPLA) legislative analyst, opened each work session with a legal and fiscal overview. On LD 253, she told the committee, "This bill repeals the current law that requires the Department of Health and Human Services to provide coverage for abortion services to MaineCare members," and reviewed how the state law interacts with federal funding riders such as the Hyde Amendment.

Why it matters: The package would change how state-funded health care, clinical reporting, criminal liability and the delivery of medication abortion are regulated in Maine. Several measures also raise implementation questions: who would enforce civil liability for drug manufacturers, how in-person requirements for medication abortion would be applied to a drug regimen spread over days, and how new reporting or list-making duties would be staffed and paid for.

What the committee did: Lawmakers debated the bills across multiple work sessions and returned several divided committee reports. A motion to repeal the MaineCare coverage requirement (LD 253) failed on a 5-6 committee vote; a motion to record "ought not to pass" on LD 682 (which would change reporting and post-viability standards and reinstate certain criminal penalties) succeeded 6-5; and other bills setting new rules for medication abortions, manufacturer liability and informed-consent language (LD 886, LD 887, LD 1007, LD 1154) drew extended technical discussion and either failed motions or no final committee report at the end of the meeting.

Details and debate

LD 253 — repeal MaineCare coverage for abortion services: Janet Sogo summarized that current law requires the Department of Health and Human Services to provide coverage for abortion services for MaineCare beneficiaries and to fund abortions not covered by federal Medicaid within existing state resources. She explained interaction with federal rules, noting the Hyde Amendment (a federal appropriations rider) does not prevent a state from using state funds to cover abortion services. Representative Jennifer Poirier moved "ought to pass," seconded by Senator Hagan. After discussion, the motion failed on a 5-6 vote (three members absent). Supporters of the repeal argued the state should not fund abortion coverage; opponents said the current law prevents discrimination against people on public insurance.

LD 682 — amend certain laws regarding reporting, post-viability exceptions and penalties: The bill would restore a narrower post-viability standard (allowing abortion after viability only where "medically necessary to preserve the life or health of the mother" and for certain lethal fetal anomalies), revise what data must be reported to DHHS (adding race, marital status and education fields to the monthly abortion report), and create or reintroduce Class C and Class D criminal penalties for unlawfully performing abortions in some circumstances. Senator Hagan, the bill sponsor, described the bill as a targeted repeal of portions of the 2023 law and added amendments to clarify drafting and align the criminal provisions with the medical exceptions. Representative Swatto moved "ought not to pass"; that motion carried 6-5. Committee members debated whether the phrase "applicable standard of care" is sufficiently specific for post-viability decisions and raised concerns from some clinicians that there is no single uniform post-viability standard of care that could be summarized in statute.

LD 886, LD 887 and LD 1007 — medication abortion, in-person oversight and manufacturer/disposal responsibilities: The committee held a combined work session because the measures overlap. - LD 886 would add informed-consent requirements and restrict online purchase of medication-abortion drugs by requiring prescriptions and in-person oversight of ingestion. Representative Henderson moved an amendment that would (among other changes) shift an online-sales prohibition to the distributor/manufacturer level and make the distributor civilly liable for violations; the committee then voted on the amended motion. The motion for "ought to pass as amended" failed 4-7. - LD 887 would make it a Class C crime for a health care provider to provide a chemical abortion without physically examining the patient, being physically present at the time of administration, scheduling a follow-up visit and providing a waste kit; it also would impose civil liability and possible penalties on drug manufacturers for environmental contamination caused by improper disposal. Committee members questioned both the statutory drafting and technical feasibility: how to define "physically present at the time of administration" for a regimen that spans days, how to trace a detected environmental metabolite to a specific manufacturer, and whether the commerce-clause language in the draft fit state law. An initial motion to re-refer LD 887 to the Environment and Natural Resources Committee failed; later, a motion to record "ought not to pass" was made and did not pass on the recorded tally. Committee members also raised jurisdictional and enforceability concerns. - LD 1007 would require that, for drug-induced abortions, providers tell patients that reversal is possible, provide a helpline number and post a DHHS-maintained website. The sponsor's proposed amendment to require documentation that the patient received general information about available reversal options and where to find services was debated; the committee recorded votes and the motion recorded in the transcript did not carry (the committee vote on the motion was 4 in favor, 7 opposed).

Committee members repeatedly asked for additional factual material: DHHS cost estimates, clinic reporting details, FDA guidance on mifepristone'misoprostol REMS and adverse-event reporting, and documentation about what perinatal hospice services exist in Maine.

LD 1154 — perinatal hospice materials: The bill would require that when an abortion is sought because of a lethal fetal-anomaly diagnosis, health care professionals provide an in-person discussion at least 24 hours before the abortion about perinatal hospice and a DHHS-maintained list of providers, and would require written certification if the patient declines hospice services. DHHS testified the agency could maintain a list but that the extent of translation and the level of detail required would affect fiscal costs. Several members said the bill risked placing procedural burdens on women and clinicians without clear evidence that the services are unavailable or undisclosed under current practices. A motion to record "ought not to pass" failed on a 4-7 recorded vote.

Votes at a glance - LD 253 (repeal MaineCare coverage): Motion: Ought to pass (moved Rep. Jennifer Poirier; second Senator Hagan). Committee tally: 5 yes, 6 no, 3 absent. Result: motion failed; committee recorded "ought not to pass." (See transcript segment introducing LD 253 and vote at the end of that work session.) - LD 682 (reporting, post-viability exceptions, penalties): Motion: Ought not to pass (moved Rep. Swatto; second Rep. Lee). Committee tally: 6 yes, 5 no, 3 absent. Result: motion carried (committee recorded "ought not to pass"). - LD 886 (medication-abortion informed consent; online restrictions): Motion: Ought to pass as amended (moved Rep. Henderson; second Rep. Caruso). Committee tally: 4 yes, 7 no, 3 absent. Result: motion failed (no committee "ought to pass" report adopted). - LD 887 (in-person presence and manufacturer disposal liability): Multiple procedural motions (attempted re-referral; reconsideration; final motions). Re-referral motion failed; subsequent motions to record reports did not produce a majority "ought to pass" record in the meeting transcript. Result in transcript: no final majority committee report adopted during the session (status: no final action recorded). - LD 1007 (informed consent language about abortion-pill reversal helpline and website): Motion: Ought to pass as amended (proposed by sponsor). Committee tally: 4 yes, 7 no, 3 absent. Result: motion failed. - LD 1154 (require perinatal hospice information for lethal fetal anomalies): Motion: Ought not to pass (moved Senator Hagan). Committee tally: 4 yes, 7 no, 3 absent. Result: motion failed.

What was left unresolved: Several committee members asked for follow-up materials that were not supplied during the meeting or were still being gathered: (1) DHHS fiscal clarity on what it would cost to maintain, translate and publish provider lists; (2) detailed Maine DHHS answers about how the state defines and tracks abortion-related adverse events; (3) documentation on whether mifepristone or misoprostol metabolites are restricted to specific products or manufacturers and whether environmental monitoring could identify particular sources; (4) additional clinical input on post-viability standards and whether a single statutory phrase would meaningfully guide clinician practice.

Where lawmakers landed: The committee divided sharply along policy lines. The only clear committee endorsement in the transcript was the "ought not to pass" report on LD 682. For the other measures, motions to change current law failed to win a committee majority or were left without a final majority report by the time the meeting ended.

Ending: Committee chairs scheduled no final floor action at the meeting and asked staff to collect the technical and fiscal follow-up requested by committee members. Several legislators said they will rely on OPLA and DHHS to produce the additional clarifying documents requested before any final reports are filed with the Legislature.